Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Wood D, Kosa K, Brown D, Ehrlich OG, Higgins PDR, Heller C. Preferences of adult patients with inflammatory bowel disease for attributes of clinical trials: evidence from a choice-based conjoint analysis. Crohns Colitis 360. 2020 Jan;2(1). doi: 10.1093/crocol/otz048
Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 Aug;7(8):723-35. doi: 10.2217/cer-2018-0003
Nguyen Thi Nhan P, Van Toan D, Que Huong T, Minh Nguyet D, Thanh Dao T, Minh Tri L, Khac Minh T, Hoc TP Y. 3D-pharmacophore modeling and its application on allosteric inhibitors of rac serin/threonin protein kinase AKT1. Journal of Ho Chi Minh City Pharmacy Association. 2018;22(S1):380-8.
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Wheeler SB, Kohler RE, Reeder-Hayes KE, Goyal RK, Lich KH, Moore A, Smith TW, Melvin CL, Muss HB. Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv. 2014 Dec;8(4):603-10. doi: 10.1007/s11764-014-0365-3
Becker N, Fortuny J, Alvaro T, Nieters A, Maynadie M, Foretova L, Staines A, Brennan P, Boffetta P, Cocco PL, de Sanjose S. Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH). J Cancer Res Clin Oncol. 2009 Aug;135(8):1099-107. doi: 10.1007/s00432-009-0551